ClinicalTrials.gg
CompletedNCT06808178LYMPHEDEMAUpdated Nov 6, 2026

EFFECT OF KINESIO TAPING AND LASER THERAPY IN PATIENT WITH LYMPHEDEMA ON GIRTH MEASUREMENT

An interventional study of Low Level Laser Therapy and kinesio taping in Lymphedema and Breast Cancer Stage II, sponsored by Beni-Suef University. Completed at 2 sites in Egypt. Open to female participants aged 40 Years to 55 Years. Per ClinicalTrials.gov, last updated 2026-11-06.

Sponsored by Beni-Suef University · Not applicable, Interventional, and Treatment

How we know

Updated Nov 6, 2026Primary completion movedPrimary outcomes revisedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
90
Allocation
Randomized
Ages
40 Years to 55 Years
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 13 studies in Lymphedema with a site in Egypt — 3 open to participants now, 4 under way, none of them phase 3. Lymphedema · Egypt.

Enrollment
Largest of 13
90 · median 60
Started
2025
with 2 others
No phase
13 of 13
3 open now
Registered
12th of 13
by date
Lead sponsor
1 of 13
Beni-Suef University

Among the 13 studies in Lymphedema with a site in Egypt, this one has the largest enrollment, is one of 3 that started in 2025, is one of 13 with no phase, and was the 12th registered.

Lymphedema

529 studies on the registry are indexed under Lymphedema; 129 are open to participants now.

Browse Lymphedema studies →

Open to participants now

3 of the 13 studies in Lymphedema with a site in Egypt are open now. Recruiting first, the newest first:

All 3 open studies →

A study can be open while its sites in Egypt have not opened yet or have stopped. Only those recruiting at a site in Egypt →

Who these studies take

Of the 84 Lymphedema studies recruiting now, 46 (55%) set no upper age limit and 21 (25%) stop at 75 or younger; 5 take children under 18; 12 take healthy volunteers.

This study: 40 Years to 55 Years · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 13 studies in Lymphedema with a site in Egypt, or all of them as a file.
02

Study summary

find out the difference in the effect of kinesio taping and low level laser therapy on 90 patients with post mastectomy lymphedema as regards the following outcomes:

1.girth measurement between the upper limbs 2.) SPADI 3) hand grip strength 4)the quality of life by cancer specific questionnaire.

Read the detailed description

90 females with BCRL will be recruited in this study for 4 weeks , their age ranged from 40 to 55 years old with stege 1,2 lymphedema and randomly divided into 3 equal groups: 2) study group (A) include 30 females with unilateral BCRL will receive kinesio taping plus manual lymphatic drainage , exercise and advices 3) study group (B) include 30 females with unilateral BCRL will receive low level laser therapy plus manual lymphatic drainage , exercise and advices 4) study group (C) include 30 females with unilateral BCRL will receive kinesio taping plus low level laser therapy and manual lymphatic drainage , exercise and advices regards the following outcomes:

1.girth measurement between the upper limbs 2.) SPADI 3) hand grip strength 4)the quality of life by cancer specific questionnaire.

03

Conditions studied

  • Lymphedema
  • Breast Cancer Stage II

Keywords

  • laser taping
04

Who can participate

Ages eligible
40 Years to 55 Years
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • persistence of lymphedema following mastectomy or breast conservative surgery for at least 3 months

    • minimum volume difference of 200 mL or an average difference in arm circumference of 2 cm or 10% between healthy and affected limbs.
    • Femal with unilateral lymphedema from 40 to 55 years old

Exclusion criteria

Exclusion Criteria:

    • Any disease lead to swelling

      • Medication especially diuretics
      • allergy
      • infection
      • pregnancy
      • heart band kidney disease
      • bilateral lymphedema
      • skin disease
      • chronic inflammatory disease
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
90 participants (actual)

Study arms

  • Experimental
    group A

    study group (A) include 30 females with unilateral BCRL will receive kinesio taping plus manual lymphatic drainage , exercise and advices

    Other: kinesio taping

  • Experimental
    Group B

    study group (B) include 30 females with unilateral BCRL will receive low level laser therapy plus manual lymphatic drainage , exercise and advices

    Device: Low Level Laser Therapy

  • Experimental
    Group C

    study group (C) include 30 females with unilateral BCRL will receive kinesio taping plus low level laser therapy and manual lymphatic drainage , exercise and advices

    Device: Low Level Laser Therapy · Other: kinesio taping

Interventions

  • DeviceLow Level Laser Therapy

    The device has the following treatment parametes : * Maximum average power \> 500 milli watts * Wave length combined (904-808) nm * Maximum repition rate (1-2000) Hz * Energy density : 4:6 J per cm per session

  • Otherkinesio taping

    * the material used is 100%acrylic,latex free and heat activated with 10-15% stretch. * It is made of 100% cotton to allow quickening of the drying process. * Ability to stretch to 120-140% of its original length * Recoil back to the anchor that is applied without stretch * Heat-activated adhesive * Hypoallergenic dyes that make the tape safe for most users * Latex-free * Drying time after being wet is about 5-10 minutes * Can be worn for several days

06

What researchers measure

Primary outcomes

  1. girth measurment

    Measurement of arm circumference is the most commonly used technique for identifying lymphedema and is reliable for both surgical and nonsurgical upper limbs It is measured using a tape with the patient in prone lying position, with elbows straight and arms relaxed at the sides. It was measured starting with 3 cm on the ulnar styloid process and proceeding with 45 cm proximal, and additionally at the metacarpal bones and mid-hand. The tape measure was put around the limb to prevent it from slacking and to ensure that there was no space in the tissue. The total circumference of the sound limb was ascertained similarly. The difference between the 2 measurements was identified using "circumference difference."

    Time frame: 4 weeks

Secondary outcomes

  1. shoulder pain and disability index

    was used to assess shoulder pain and disability. It incorporates 13 items assessing 2 domains: 5 items assess pain and 8 items evaluate disability.

    Time frame: 4 weeks

  2. quality of life questionnaire

    was assessed by cancer-specific questionnaire (EORTC QLQ-C30). It is composed of 30 questions, including functional scores (physical, social, emotional, and cognitive aspects). The functional scores ranged between 0 and 100, and higher scores indicated better condition. This questionnaire also included symptoms score (pain, dyspnea, fatigue, insomnia, nausea, loss of appetite, and financial problems). The symptom scores ranged from 100 to 0, and lower scores indicated better condition

    Time frame: 4 weeks

  3. handgrip strength

    evaluated using a dynamometer ,The grip strength was measured with the patient in a standing position with adducted shoulder, elbow flexed at 90°, and forearm in mid position. The patient was instructed to do 3 trials with 15 seconds rest in between each, and the highest reading was reported

    Time frame: 4 week

07

Study locations

2 sites
  • Cairo University Hospital
    Cairo, Cairo Governorate 11865, Egypt
  • Cairo -Beni-Suif University Hospital
    GIZA, Cairo Governorate 11865, Egypt
08

Timeline

2 registry updates since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Feb 2025 to primary completion in Sep 2025, 7 months.

Of 175 non-industry interventional studies with no phase under Lymphedema, half reached primary completion within 27 months of starting (the median), counting those still running; a quarter within 11 and three quarters within 68. This study's 7 months is below that.

Counting every sponsor, half of 197 studies reached it within 25 months; a quarter within 11 and three quarters within 64.

Primary completion moved once since we started tracking on Sep 25, 2026: Jun 2025 → Sep 2025, on Nov 6, 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Jan 29, 2025
First posted
Feb 5, 2025
StartActual
Feb 1, 2025
Primary completionActual
Sep 1, 2025was Jun 2025
CompletionActual
Sep 1, 2025
Last update
Nov 6, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Primary completion
Jun 1, 2025→Sep 1, 2025
Nov 6, 2026
Primary outcomes
1 removed
What changed in the outcomes
  • Removedhandgrip strengthTime frame: 4 weeks
Nov 4, 2026
Secondary outcomes
1 added
What changed in the outcomes
  • Addedhandgrip strengthTime frame: 4 week
Nov 4, 2026
Show all 2 updates
  1. Nov 6, 2026
    Primary completion Jun 1, 2025→Sep 1, 2025
    + 3 other changes: verification date, description and design details
  2. Nov 4, 2026
    Primary outcomes 1 removed
    What changed in the outcomes
    • Removedhandgrip strengthTime frame: 4 weeks
    Secondary outcomes 1 added
    What changed in the outcomes
    • Addedhandgrip strengthTime frame: 4 week
    + 2 other changes: description and design details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT06808178
Responsible party
Mahmoud Awad Ramadan Elkholy (Lecturer of physical therapy, Beni-Suef University) — Principal investigator
First posted
Feb 5, 2025
Start date
Feb 1, 2025
Primary completion
Sep 1, 2025
Completion
Sep 1, 2025
Last update
Nov 6, 2026

Study contacts

MERIT MAGDY ZAKI, physiotherapist
principal investigator · beni suif university
SHERIN HASSAN MEHANI, Professor of Physical therapy
study chair · beni suif university
MAHMOUD AWD ELKHOLY, Lecturer of physical therapy
study director · beni suif university

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion